Pilot Study: Creating Antibody-Drug Linkages

AvidBiologics有兴趣开发产品，直接抗癌药物专门针对肿瘤中的癌细胞。在此过程中，他们获得了一组抗体蛋白，这些抗体蛋白已被证明可以与恶性肿瘤结合。多伦多大学提出的这项研究将开发出将药物化学附着在这些抗体上的方法，这样药物就可以被特异性地引导到所需的作用部位。该项目包括设计用作连接试剂的化学物质，生产所需的化学物质，然后开发附着抗癌药物的工艺。由此产生的药物连接试剂将被测试其与细胞靶向抗体特异性反应的能力，并且成功生产的材料将由AvidBiologics进行评估。这是一项介绍性研究，以确定该方法的可行性，并建立协作努力，如果获得的结果证明进一步的工作是合理的。

AvidBiologics is interested in developing products that direct anti-cancer drugs specifically to target cancer cells in tumors. In doing so, they have acquired a collection of antibody proteins that have been shown to bind to malignant tumors. The proposed research at the University of Toronto will develop ways to attach drugs chemically to those antibodies, so that the drug can be guided specifically to the desired site of action. The project involves designing the chemicals to be used as connecting reagents, producing the desired chemicals, and then developing a process for attaching anti-cancer drugs. The resulting drug-linked reagents will then be tested for their ability to react specifically with the cell-targeting antibodies and the successfully produced materials will be evaluated by AvidBiologics. This is an introductory study to determine the feasibility of the approach and to establish a collaborative effort should the results obtained justify further work.